SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) June 7, 2001
------------
ALEXION PHARMACEUTICALS, INC.
-----------------------------
(Exact Name of Registrant as Specified in its Charter)
DELAWARE 0-27756 13-3648318
-------------------- -------------- ------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
352 KNOTTER DRIVE CHESHIRE, CT 06410
---------------------------------------- -----
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (203) 272-2596
--------------
NOT APPLICABLE
--------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS
On June 7, 2001, Alexion Pharmaceuticals, Inc. issued the press releases
filed herewith as Exhibit 99.1 and Exhibit 99.2.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(C) EXHIBITS.
99.1 Press Release dated June 7, 2001.
99.2 Press Release dated June 7, 2001.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ALEXION PHARMACEUTICALS, INC.
Date: June 7, 2001 By: /s/ LEONARD BELL, M.D.
-----------------------------------------
Name: Leonard Bell, M.D.
Title: President, Chief Executive Officer,
Secretary and Treasurer
EXHIBIT INDEX
99.1 Press Release dated June 7, 2001.
99.2 Press Release dated June 7, 2001